The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis.
hepatitis B
hepatitis B immunoglobulin
hepatitis delta
liver transplantation
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
15 Dec 2023
15 Dec 2023
Historique:
revised:
04
10
2023
received:
12
07
2023
accepted:
23
10
2023
medline:
15
12
2023
pubmed:
15
12
2023
entrez:
15
12
2023
Statut:
aheadofprint
Résumé
Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement
ID : 2017_SGR_1753
Organisme : Asociación Española para el Estudio del Hígado
Organisme : CERCA Programme/Generalitat de Catalunya
Organisme : Instituto de Salud Carlos III
ID : PI22/00013
Organisme : Instituto de Salud Carlos III
ID : PI18/00079
Organisme : Instituto de Salud Carlos III
ID : PI20/00609
Organisme : Societat Catalana de Digestologia
Informations de copyright
Liver International© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378(9785):73-85.
Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18(6):434-442.
Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis δ infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629-1638.
Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46(3):420-426.
Dietz-Fricke C, Tacke F, Zöllner C, et al. Treating hepatitis D with bulevirtide-real-world experience from 114 patients. JHEP Rep. 2023;5(4):100686.
Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol. 2013;58(2):287-296.
Duvoux C, Belli LS, Fung J, et al. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. Aliment Pharmacol Ther. 2021;54(5):583-605.
Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329(25):1842-1847.
Martini S, Caccamo L, Rizzetto M. Are immunoglobulins against the HBsAg still needed in liver transplantation for hepatitis D? Hepatology. 2018;67(6):2475-2476.
Martini S, Tandoi F, Romagnoli R, Rizzetto M. Liver transplantation in hepatitis B/hepatitis D (Delta) virus coinfected recipients. Transplantation. 2022;106(10):1935-1939.
Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28:585-589.
Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011;141:1212-1219.
Cheung CK, Lo CM, Man K, Lau GK. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl. 2010;16:1314-1323.
Taylor JM. Virology of hepatitis D virus. Semin Liver Dis. 2012;32(3):195-200.
Lens S, García-Eliz M, Fernández I, et al. Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. Liver Int. 2018;38(11):1940-1950.
Fung J, Chan SC, Cheung C, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol. 2013;108(6):942-948.
Lenci I, Tariciotti L, Angelico R, et al. Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins. Clin Transplant. 2023;37(6):e14971.
Mederacke I, Filmann N, Yurdaydin C, et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol. 2012;56(1):115-122.
Giersch K, Bhadra OD, Volz T, et al. Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. Gut. 2019;68(1):150-157.
Lempp FA, Schlund F, Rieble L, et al. Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation. Nat Commun. 2019;10(1):2265.